DK2720698T3 - PROCEDURE FOR ADMINISTRATING 4 - ((1R, 3S) -6-CHLOR-3-PHENYL-INDAN-1-YL) -1,2,2-TRIMETHYL-PIPERAZINE AND THE SALTS THEREOF IN THE TREATMENT OF SCHIZOPHERENIA - Google Patents
PROCEDURE FOR ADMINISTRATING 4 - ((1R, 3S) -6-CHLOR-3-PHENYL-INDAN-1-YL) -1,2,2-TRIMETHYL-PIPERAZINE AND THE SALTS THEREOF IN THE TREATMENT OF SCHIZOPHERENIA Download PDFInfo
- Publication number
- DK2720698T3 DK2720698T3 DK12729555.8T DK12729555T DK2720698T3 DK 2720698 T3 DK2720698 T3 DK 2720698T3 DK 12729555 T DK12729555 T DK 12729555T DK 2720698 T3 DK2720698 T3 DK 2720698T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- dose
- weekly
- disorder
- treatment
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 31
- BYPMJBXPNZMNQD-PZJWPPBQSA-N Zicronapine Chemical compound C1C(C)(C)N(C)CCN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 BYPMJBXPNZMNQD-PZJWPPBQSA-N 0.000 title description 4
- 238000000034 method Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 86
- 208000028017 Psychotic disease Diseases 0.000 claims description 41
- 230000003442 weekly effect Effects 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 201000000980 schizophrenia Diseases 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 208000024891 symptom Diseases 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 238000009472 formulation Methods 0.000 claims description 9
- 239000012458 free base Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 208000020925 Bipolar disease Diseases 0.000 claims description 8
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 8
- 206010026749 Mania Diseases 0.000 claims description 4
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 4
- 208000019568 Shared Paranoid disease Diseases 0.000 claims description 4
- 208000028810 Shared psychotic disease Diseases 0.000 claims description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 4
- 230000003111 delayed effect Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 229960003878 haloperidol Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000022610 schizoaffective disease Diseases 0.000 claims description 4
- 229960004170 clozapine Drugs 0.000 claims description 3
- 239000003176 neuroleptic agent Substances 0.000 claims description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- 229950009875 osanetant Drugs 0.000 claims 2
- DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 claims 2
- 229960004431 quetiapine Drugs 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229960000652 sertindole Drugs 0.000 claims 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 claims 2
- 229960000607 ziprasidone Drugs 0.000 claims 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000035474 group of disease Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 101150049660 DRD2 gene Proteins 0.000 description 20
- 230000027455 binding Effects 0.000 description 14
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 230000000561 anti-psychotic effect Effects 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 239000002287 radioligand Substances 0.000 description 6
- 108090000511 Dopamine D1 Receptors Proteins 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229950001518 raclopride Drugs 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 239000012131 assay buffer Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 230000000698 schizophrenic effect Effects 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 description 3
- 108091005479 5-HT2 receptors Proteins 0.000 description 3
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 230000009798 acute exacerbation Effects 0.000 description 3
- 230000008485 antagonism Effects 0.000 description 3
- 239000000164 antipsychotic agent Substances 0.000 description 3
- 210000001638 cerebellum Anatomy 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011418 maintenance treatment Methods 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229950009086 zicronapine Drugs 0.000 description 3
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 2
- 108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
- 208000021465 Brief psychotic disease Diseases 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 208000024254 Delusional disease Diseases 0.000 description 2
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 2
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000027776 Extrapyramidal disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 208000002851 paranoid schizophrenia Diseases 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 210000002637 putamen Anatomy 0.000 description 2
- -1 see table 5 Chemical class 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GOTMKOSCLKVOGG-RHHLBCDKSA-N (5r)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)[11CH3])=CC=CC=C1 GOTMKOSCLKVOGG-RHHLBCDKSA-N 0.000 description 1
- FBCSWIXKXHSYBN-UHFFFAOYSA-N 1-(6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl)-3,3-dimethylpiperazine Chemical compound C1CNC(C)(C)CN1C1C2=CC(Cl)=CC=C2C(C=2C=CC=CC=2)C1 FBCSWIXKXHSYBN-UHFFFAOYSA-N 0.000 description 1
- WAOQONBSWFLFPE-TXWZUYSVSA-N 3,5-dichloro-n-[[(2s)-1-ethylpyrrolidin-2-yl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1O[11CH3] WAOQONBSWFLFPE-TXWZUYSVSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003379 hyperdopaminergic effect Effects 0.000 description 1
- 208000031424 hyperprolactinemia Diseases 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 150000002468 indanes Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 108010024941 iodothyronine deiodinase type II Proteins 0.000 description 1
- 230000002197 limbic effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 125000005489 p-toluenesulfonic acid group Chemical class 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003890 succinate salts Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161498653P | 2011-06-20 | 2011-06-20 | |
| DKPA201100465 | 2011-06-20 | ||
| PCT/EP2012/061779 WO2012175531A1 (en) | 2011-06-20 | 2012-06-20 | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2720698T3 true DK2720698T3 (en) | 2018-11-26 |
Family
ID=58794324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12729555.8T DK2720698T3 (en) | 2011-06-20 | 2012-06-20 | PROCEDURE FOR ADMINISTRATING 4 - ((1R, 3S) -6-CHLOR-3-PHENYL-INDAN-1-YL) -1,2,2-TRIMETHYL-PIPERAZINE AND THE SALTS THEREOF IN THE TREATMENT OF SCHIZOPHERENIA |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9610287B2 (enExample) |
| EP (1) | EP2720698B1 (enExample) |
| JP (1) | JP6140151B2 (enExample) |
| KR (1) | KR101900989B1 (enExample) |
| CN (1) | CN103608015A (enExample) |
| AU (1) | AU2012274150B2 (enExample) |
| BR (1) | BR112013032178A2 (enExample) |
| CA (1) | CA2838055C (enExample) |
| DK (1) | DK2720698T3 (enExample) |
| ES (1) | ES2694298T3 (enExample) |
| HR (1) | HRP20181684T1 (enExample) |
| IL (1) | IL230060A (enExample) |
| JO (1) | JO3421B1 (enExample) |
| LT (1) | LT2720698T (enExample) |
| MX (1) | MX349754B (enExample) |
| PL (1) | PL2720698T3 (enExample) |
| RS (1) | RS57944B1 (enExample) |
| RU (1) | RU2613177C2 (enExample) |
| SI (1) | SI2720698T1 (enExample) |
| SM (1) | SMT201800567T1 (enExample) |
| TW (1) | TWI552751B (enExample) |
| WO (1) | WO2012175531A1 (enExample) |
| ZA (1) | ZA201309617B (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7402400B2 (en) | 2001-07-03 | 2008-07-22 | Regents Of The University Of California | Mammalian sweet taste receptors |
| EP1230344B1 (en) | 1999-11-17 | 2011-11-02 | Mendel Biotechnology, Inc. | Plant biochemistry-related genes |
| US6458538B1 (en) | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
| TW201006846A (en) | 2000-03-07 | 2010-02-16 | Senomyx Inc | T1R taste receptor and genes encidung same |
| WO2002015675A1 (en) | 2000-08-22 | 2002-02-28 | Mendel Biotechnology, Inc. | Genes for modifying plant traits iv |
| US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| US7883856B2 (en) | 2001-04-05 | 2011-02-08 | Senomyx Inc. | Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators |
| CA2451317C (en) | 2001-06-26 | 2016-03-29 | Senomyx, Inc. | T1r hetero-oligomeric taste receptors and cell lines that express said receptors and use thereof for identification of taste compounds |
| US7871619B2 (en) | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| EP1572121B1 (en) | 2002-08-01 | 2012-01-11 | The Regents of The University of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
| AU2003285856A1 (en) | 2002-09-18 | 2004-04-23 | Mendel Biotechnology, Inc. | Polynucleotides and polypeptides in plants |
| PT1629088E (pt) | 2003-05-30 | 2012-04-10 | Agensys Inc | Variantes de antigénio de células estaminais de próstata (psca) e subsequências das mesmas |
| EP2369347A1 (en) | 2003-11-07 | 2011-09-28 | Ciphergen Biosystems, Inc. | Biomarkers for Alzheimer's disease |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| ES2671522T3 (es) | 2004-04-02 | 2018-06-06 | The Regents Of The University Of California | Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5 |
| US7939251B2 (en) | 2004-05-06 | 2011-05-10 | Roche Molecular Systems, Inc. | SENP1 as a marker for cancer |
| MXPA06013834A (es) | 2004-05-28 | 2007-03-01 | Agensys Inc | Anticuerpos y moleculas relacionadas que enlazan a proteinas psca. |
| WO2006002262A2 (en) | 2004-06-21 | 2006-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder |
| US7850960B2 (en) | 2004-12-30 | 2010-12-14 | University Of Washington | Methods for regulation of stem cells |
| JP2008528060A (ja) | 2005-01-27 | 2008-07-31 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ボツリヌス神経毒素を中和する治療的モノクローナル抗体 |
| AU2006230563B8 (en) | 2005-03-31 | 2010-06-17 | Agensys, Inc. | Antibodies and related molecules that bind to 161P2F10B proteins |
| CA2790675C (en) | 2005-07-19 | 2016-12-20 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif and bmps |
| WO2007047988A2 (en) | 2005-10-20 | 2007-04-26 | Senomyx, Inc. | Chimeric human sweet-umami and umami-sweet taste receptors |
| CN101500592A (zh) | 2005-11-07 | 2009-08-05 | 斯克利普斯研究院 | 控制组织因子信号转导特异性的组合物和方法 |
| EP2564864B8 (en) | 2005-11-12 | 2015-05-13 | The Board of Trustees of The Leland Stanford Junior University | FGF2-related methods for diagnosing and treating depression |
| CN103301475B (zh) | 2005-12-28 | 2016-08-03 | 斯克里普斯研究所 | 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用 |
| US20100278821A1 (en) | 2006-03-21 | 2010-11-04 | The Regents Of The University Of California | N-cadherin: target for cancer diagnosis and therapy |
| WO2007109347A2 (en) | 2006-03-21 | 2007-09-27 | The Regents Of The University Of California | N-cadherin and ly6 e: targets for cancer diagnosis and therapy |
| US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
| EP2423333A1 (en) | 2006-08-25 | 2012-02-29 | Oncotherapy Science, Inc. | Prognostic markers and therapeutic targets for lung cancer |
| AU2007292219B2 (en) | 2006-09-06 | 2014-04-24 | The Regents Of The University Of California | Molecular diagnosis and classification of malignant melanoma |
| US8575663B2 (en) | 2006-11-22 | 2013-11-05 | President And Fellows Of Harvard College | High-sensitivity nanoscale wire sensors |
| AU2008287542C1 (en) | 2007-06-01 | 2015-01-22 | The Trustees Of Princeton University | Treatment of viral infections by modulation of host cell metabolic pathways |
| EP2522754B1 (en) | 2007-08-13 | 2014-04-02 | Baxter International Inc. | IVIG modulation of chemokines for treatment of Multiple Sclerosis, Alzheimer's disease, and Parkinson's disease |
| KR101599715B1 (ko) | 2007-08-21 | 2016-03-08 | 세노믹스, 인코포레이티드 | 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도 |
| JP5496897B2 (ja) | 2007-10-04 | 2014-05-21 | ザイモジェネティクス， インコーポレイテッド | Ｂ７ファミリーメンバーのｚＢ７Ｈ６ならびに関連する組成物および方法 |
| EP2924435A3 (en) | 2007-10-22 | 2015-11-04 | The Regents of The University of California | Biomarkers for prenatal diagnosis of congenital cytomegalovirus |
| WO2009062112A2 (en) | 2007-11-09 | 2009-05-14 | The Salk Institute For Biological Studies | Use of tam receptor inhibitors as antimicrobials |
| CN102027105B (zh) | 2008-03-17 | 2015-03-11 | 斯克里普斯研究所 | 用于产生诱导的多能干细胞的组合化学遗传方法 |
| ES2613844T3 (es) | 2008-04-21 | 2017-05-26 | Lawrence Livermore National Security, Llc | Ligandos polidentados de alta afinidad selectivos y métodos para producirlos |
| WO2010017248A2 (en) | 2008-08-04 | 2010-02-11 | University Of Miami | Sting (stimulator of interferon genes), a regulator of innate immune responses |
| CA2738019A1 (en) | 2008-09-23 | 2010-04-08 | President And Fellows Of Harvard College | Sirt4 and uses thereof |
| WO2010054189A1 (en) | 2008-11-06 | 2010-05-14 | University Of Miami | Role of soluble upar in the pathogenesis of proteinuric kidney disease |
| US8735082B2 (en) | 2008-11-10 | 2014-05-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Gene signature for predicting prognosis of patients with solid tumors |
| CN105001196B (zh) | 2008-12-03 | 2017-05-10 | 斯克里普斯研究所 | 干细胞培养 |
| ES2645869T3 (es) | 2008-12-17 | 2017-12-11 | The Scripps Research Institute | Generación y mantenimiento de células madre |
| KR20110140128A (ko) | 2009-03-27 | 2011-12-30 | 고조 인더스트리즈, 인크 | 포자-표면 상호작용을 길항하는 화합물을 스크리닝 및 사용하기 위한 조성물 및 방법 |
| KR101752515B1 (ko) | 2009-07-24 | 2017-06-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | Ａｖｂ５ 인테그린과 결부된 질환의 치료 및 예방을 위한 방법 및 조성물 |
| CN102576022B (zh) | 2009-08-14 | 2016-06-15 | 加利福尼亚大学董事会 | 诊断和治疗自闭症的方法 |
| WO2011022638A1 (en) | 2009-08-20 | 2011-02-24 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
| WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
| ES2365343B1 (es) | 2009-11-19 | 2012-07-10 | Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii | Uso de cd98 como marcador de receptividad endometrial. |
| US20130137584A1 (en) | 2010-02-01 | 2013-05-30 | The Regents Of The University Of California | Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies |
| WO2012052391A1 (en) | 2010-10-19 | 2012-04-26 | Glaxo Group Limited | Polypeptide with jmjd3 catalytic activity |
| WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
| WO2012119989A2 (en) | 2011-03-04 | 2012-09-13 | Oryzon Genomics, S.A. | Methods and antibodies for the diagnosis and treatment of cancer |
| US20120301904A1 (en) | 2011-04-26 | 2012-11-29 | Prosetta Antiviral, Inc | Multiprotein assemblies |
| EP2825209B1 (en) | 2012-03-14 | 2018-08-29 | University of Central Florida Research Foundation, Inc. | Neurofibromatoses therapeutic agents and screening for same |
| JP6399660B2 (ja) | 2012-04-10 | 2018-10-03 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 癌治療用組成物および方法 |
| AU2013252909B2 (en) | 2012-04-24 | 2017-09-28 | University Of Miami | Perforin 2 defense against invasive and multidrug resistant pathogens |
| US20150164800A1 (en) | 2012-07-25 | 2015-06-18 | Xetrios Therapeutics, Inc. | Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine |
| EP2890370B1 (en) | 2012-08-31 | 2019-10-09 | The Regents of the University of California | Agents useful for treating obesity, diabetes and related disorders |
| AU2013204200B2 (en) | 2012-10-11 | 2016-10-20 | Brandeis University | Treatment of amyotrophic lateral sclerosis |
| US20140120116A1 (en) | 2012-10-26 | 2014-05-01 | The Chinese University Of Hong Kong | Treatment of cancer using smad3 inhibitor |
| US20140243356A1 (en) | 2013-02-07 | 2014-08-28 | The Regents Of The University Of California | Use of translational profiling to identify target molecules for therapeutic treatment |
| WO2014144844A1 (en) | 2013-03-15 | 2014-09-18 | The Board Of Trustees Of The Leland Stanford Junior University | tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY |
| CA2933590C (en) | 2013-12-11 | 2023-10-03 | Sloan-Kettering Institute For Cancer Research | Glucocorticoid inhibitors for treatment of prostate cancer |
| ES2713196T3 (es) | 2013-12-11 | 2019-05-20 | Biogen Ma Inc | Compuestos de biarilo útiles para el tratamiento de enfermedades humanas en oncología, neurología e inmunología |
| WO2015136509A2 (en) | 2014-03-14 | 2015-09-17 | Genesis Theranostix Korlatolt Felelossegu Tarsasag | Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy |
| US10196701B2 (en) | 2015-06-01 | 2019-02-05 | The Penn State Research Foundation | Hepatitis B virus capsid assembly |
| US10782304B2 (en) | 2015-06-24 | 2020-09-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for detecting protein-protein interactions |
| WO2018036503A1 (en) | 2016-08-25 | 2018-03-01 | The Chinese University Of Hong Kong | Fecal bacterial markers for colorectal cancer |
| JP7191828B2 (ja) | 2016-12-15 | 2022-12-19 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | がん治療のための組成物および方法 |
| US11555031B2 (en) | 2017-03-20 | 2023-01-17 | The Broad Institute, Inc. | Compounds and methods for regulating insulin secretion |
| EP3606548A4 (en) | 2017-04-04 | 2021-03-24 | Loma Linda University | BIOLOGICAL AGENT FOR THE TREATMENT OF CANCER |
| US20210247386A1 (en) | 2018-04-26 | 2021-08-12 | Technion Research & Development Foundation Limited | A device and method for determining cell indentation activity |
| AU2019373090B2 (en) | 2018-10-31 | 2023-05-25 | The University Of Sydney | Compositions and methods for treating viral infections |
| US11325978B2 (en) | 2018-11-06 | 2022-05-10 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for treating beta-globinopathies |
| EP4247427A4 (en) | 2020-11-19 | 2025-04-09 | The Chinese University of Hong Kong | Assessing risk for colorectal adenoma recurrence by noninvasive means |
| WO2023081167A2 (en) | 2021-11-02 | 2023-05-11 | The Regents Of The University Of California | P-selectin mutants and modulation of integrin-mediated signaling |
| US20250092106A1 (en) | 2022-01-25 | 2025-03-20 | The Regents Of The University Of California | Vegf mutants and modulation of integrin-mediated signaling |
| WO2024197185A1 (en) | 2023-03-21 | 2024-09-26 | The Broad Institute, Inc. | Methods and compositions for dissecting organelle physiology |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| BRPI0413555A (pt) | 2003-08-18 | 2006-10-17 | Lundbeck & Co As H | composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto |
| WO2007011955A2 (en) | 2005-07-18 | 2007-01-25 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| MXPA06012059A (es) * | 2004-04-22 | 2007-01-25 | Boehringer Ingelheim Int | Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii. |
| US20090306092A1 (en) * | 2008-05-07 | 2009-12-10 | H. Lundbeck A/S | Method for treating cognitive deficits |
| AU2009298264A1 (en) * | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
| EP2453870A2 (en) * | 2009-06-24 | 2012-05-23 | MSD Oss B.V. | Injectable formulations containing asenapine and method of treatment using same |
-
2012
- 2012-06-19 JO JOP/2012/0162A patent/JO3421B1/ar active
- 2012-06-19 TW TW101121870A patent/TWI552751B/zh not_active IP Right Cessation
- 2012-06-20 KR KR1020137033338A patent/KR101900989B1/ko not_active Expired - Fee Related
- 2012-06-20 US US14/126,499 patent/US9610287B2/en active Active
- 2012-06-20 SI SI201231436T patent/SI2720698T1/sl unknown
- 2012-06-20 CN CN201280029452.1A patent/CN103608015A/zh active Pending
- 2012-06-20 PL PL12729555T patent/PL2720698T3/pl unknown
- 2012-06-20 DK DK12729555.8T patent/DK2720698T3/en active
- 2012-06-20 SM SM20180567T patent/SMT201800567T1/it unknown
- 2012-06-20 EP EP12729555.8A patent/EP2720698B1/en active Active
- 2012-06-20 LT LTEP12729555.8T patent/LT2720698T/lt unknown
- 2012-06-20 JP JP2014516318A patent/JP6140151B2/ja active Active
- 2012-06-20 CA CA2838055A patent/CA2838055C/en not_active Expired - Fee Related
- 2012-06-20 RS RS20181311A patent/RS57944B1/sr unknown
- 2012-06-20 WO PCT/EP2012/061779 patent/WO2012175531A1/en not_active Ceased
- 2012-06-20 ES ES12729555.8T patent/ES2694298T3/es active Active
- 2012-06-20 AU AU2012274150A patent/AU2012274150B2/en not_active Ceased
- 2012-06-20 BR BR112013032178A patent/BR112013032178A2/pt not_active Application Discontinuation
- 2012-06-20 MX MX2013014978A patent/MX349754B/es active IP Right Grant
- 2012-06-20 RU RU2014101482A patent/RU2613177C2/ru active
- 2012-06-20 HR HRP20181684TT patent/HRP20181684T1/hr unknown
-
2013
- 2013-12-19 IL IL230060A patent/IL230060A/en active IP Right Grant
- 2013-12-19 ZA ZA2013/09617A patent/ZA201309617B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JO3421B1 (ar) | 2019-10-20 |
| IL230060A (en) | 2017-10-31 |
| ES2694298T3 (es) | 2018-12-19 |
| RU2014101482A (ru) | 2015-07-27 |
| KR20140033419A (ko) | 2014-03-18 |
| JP2014517050A (ja) | 2014-07-17 |
| SI2720698T1 (sl) | 2018-12-31 |
| RU2613177C2 (ru) | 2017-03-15 |
| EP2720698B1 (en) | 2018-10-03 |
| US9610287B2 (en) | 2017-04-04 |
| US20140194409A1 (en) | 2014-07-10 |
| CN103608015A (zh) | 2014-02-26 |
| CA2838055C (en) | 2021-01-26 |
| RS57944B1 (sr) | 2019-01-31 |
| KR101900989B1 (ko) | 2018-09-20 |
| MX2013014978A (es) | 2014-04-10 |
| HRP20181684T1 (hr) | 2018-12-14 |
| MX349754B (es) | 2017-08-11 |
| LT2720698T (lt) | 2018-11-12 |
| AU2012274150B2 (en) | 2016-10-06 |
| AU2012274150A1 (en) | 2014-01-09 |
| ZA201309617B (en) | 2015-04-29 |
| TW201306840A (zh) | 2013-02-16 |
| TWI552751B (zh) | 2016-10-11 |
| WO2012175531A1 (en) | 2012-12-27 |
| JP6140151B2 (ja) | 2017-05-31 |
| EP2720698A1 (en) | 2014-04-23 |
| BR112013032178A2 (pt) | 2016-12-20 |
| PL2720698T3 (pl) | 2019-01-31 |
| SMT201800567T1 (it) | 2018-11-09 |
| CA2838055A1 (en) | 2012-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2720698T3 (en) | PROCEDURE FOR ADMINISTRATING 4 - ((1R, 3S) -6-CHLOR-3-PHENYL-INDAN-1-YL) -1,2,2-TRIMETHYL-PIPERAZINE AND THE SALTS THEREOF IN THE TREATMENT OF SCHIZOPHERENIA | |
| Potkin et al. | Efficacy and tolerability of asenapine in acute schizophrenia: a placebo-and risperidone-controlled trial. | |
| Miyamoto et al. | Antipsychotic drugs | |
| Gareri et al. | Use of atypical antipsychotics in the elderly: a clinical review | |
| Fernandez et al. | Treatment of psychosis in Parkinson’s disease: safety considerations | |
| Tarsy et al. | Effects of newer antipsychotics on extrapyramidal function | |
| CA2332814C (en) | Combination therapy for treatment of refractory depression | |
| Teegarden et al. | 5-HT2A inverse-agonists for the treatment of insomnia | |
| US6960577B2 (en) | Combination therapy for treatment of refractory depression | |
| R Moore et al. | Pharmacogenomics in psychiatry: implications for practice | |
| Albers et al. | Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? | |
| HUP0402619A2 (hu) | Norepinefrin re-uptake inhibitorok alkalmazása a megértési nehézségek kezelésére használható gyógyszer előállítására | |
| HK1196083A (en) | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia | |
| HK1196083B (en) | Method of administration of 4-((1r,3s)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and the salts thereof in the treatment of schizophrenia | |
| Ananth et al. | Drug therapy in schizophrenia | |
| McIntyre | Asenapine: a review of acute and extension phase data in bipolar disorder | |
| Sánchez et al. | Preclinical effects of antipsychotic drugs | |
| Cetin | Asenapine: A novel hope in the treatment of schizophrenia and manic and mixed episodes of bipolar I disorder | |
| Orsolini et al. | Atypical antipsychotics in major depressive disorder | |
| TR201816155T4 (tr) | Şizofreni tedavisinde 4-((1r,3s)-6-kloro-3-fenil-indan-1-il)-1,2,2-trimetil-piperazin ve bunların tuzlarının uygulanmasına yönelik yöntem. | |
| Mauri | Antidepressant Efficacy of the Antipsychotic Quetiapine: Pharmacokinetics, Pharmacodynamics and Clinical Data | |
| Jethwa | Antipsychotics for the management of Parkinson's disease psychosis | |
| Remington | ‘Atypical’antipsychotics: where does ziprasidone fit? | |
| Canu | Action of atypical antipsychotics on body weight and associated metabolic factors | |
| Zacher et al. | Iloperidone: Efficacy Review for the Acute Treatment of Schizophrenia in Adults. |